Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Source: SeekingAlpha
2026-06-01 17:14:08 ET
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer June 1, 2026 8:30 AM EDT...
Read the full article on Seeking Alpha
For further details see:
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte Inc.
NASDAQ: VCYT
VCYT Trading
3.04% G/L:
$47.95 Last:
256,856 Volume:
$47.77 Open:
VCYT Latest News
VCYT Stock Data
$2,908,219,075
77,942,485
0.94%
127
N/A
Medical Diagnostics & Screening
Healthcare
US
South San Francisco
